Plus   Neg

Stock Alert: Eli Lilly And Company Jumps 11%

Shares of drug maker Eli Lilly and Company (LLY) are climbing more than 11% Monday morning on the news of FDA accepting supplemental New Drug Application for its type 2 diabetes treatment Jardiance.

Jardiance (empagliflozin) is currently being investigated as a potential new treatment for adults with chronic heart failure with reduced ejection fraction, including those with and without type 2 diabetes.

In 2014, Jardiance was approved to be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes and to reduce the risk of cardiovascular death in adults with type 2 diabetes and known cardiovascular disease. The drug is marketed by Boehringer Ingelheim and Eli Lilly.

The FDA previously granted Fast Track designation to Jardiance for the reduction of the risk of cardiovascular death and hospitalization for heart failure in people with heart failure. This designation is for EMPEROR-Reduced and EMPEROR-Preserved trials. The sNDA was based on results from the EMPEROR-Reduced phase III trial and the EMPEROR-Preserved results are expected in 2021.

In March 2020, the FDA had granted Fast Track designation to Jardiance for the treatment of chronic kidney disease. This designation covers the ongoing EMPA-KIDNEY trial, the results of which are expected in 2022.

LLY stock, currently at $184.86, has traded in the range of $117.06- $189.3 in the last one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Editors Pick
Chico's FAS Inc. (CHS) Tuesday reported a wider year-over-year net loss for the fourth quarter. Meanwhile, Kohl's Corp.'s (KSS) fourth-quarter net income grew 29 percent from the previous year. But Abercrombie & Fitch Co.'s (ANF) fourth-quarter net income decreased 1 percent from the prior year. The U.S. Food and Drug Administration has approved the marketing of a new robotically-assisted surgical device (RASD) that can facilitate transvaginal hysterectomy in certain patients using minimally-invasive surgical instruments. The Hominis Surgical System of Memic Innovative Surgery Ltd., the U.S. subsidiary of Israeli biotechnology company memic Ltd., has been granted marketing authorization. Canadian cannabis company Canopy Growth Corp. (CGC, WEED.TO) announced Tuesday the launch of its Cannabidiol (CBD) beverage brand Quatreau in the high-potential U.S. market. Quatreau will be sold on Canopy's one-stop U.S. e-commerce destination, www.shopcanopy.com. Quatreau is a premium ready-to-drink...
Follow RTT